logo
Twitter
Discord
Email
logo
The Cigna Group

The Cigna Group

NYSE•CI
CEO: Mr. David Michael Cordani
Sector: Healthcare
Industry: Medical - Healthcare Plans
Listing Date: 1982-03-31
The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. In addition, it offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Contact Information
900 Cottage Grove Road, Bloomfield, CT, 06002, United States
860-226-6000
www.cigna.com
Market Cap
$73.42B
P/E (TTM)
11.9
46.8
Dividend Yield
2.2%
52W High
$350.00
52W Low
$239.51
52W Range
32%
Rank17Top 2.9%
6.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$69.75B+9.50%
4-Quarter Trend

EPS

$7.02+164.91%
4-Quarter Trend

FCF

$3.14B-989.52%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Total Revenue Growth Total Revenues reached $202.4B USD, increasing 12% for nine months ended September 30, 2025.
Shareholders' Net Income Surge Shareholders' Net Income $1.97B USD for three months, surging 153% from prior year comparison period.
Evernorth Segment Performance Evernorth adjusted income $5.03B USD, growing 4% for nine months, driven by Pharmacy Benefit Services.
HCSC Divestiture Gain Recognized $79M pre-tax gain on HCSC divestiture for nine months period ending September 30, 2025.

Risk Factors

Rising Medical Cost Trend Medical Care Ratio rose 160 bps for nine months due to higher expected stop loss medical costs.
Premiums Decline Post-Divestiture Premiums fell 21% (3M) and 10% (9M) reflecting significant impact from the HCSC transaction completion.
Debt Capitalization Ratio Debt-to-Capitalization ratio stands at 44.9% as of September 30, 2025, requiring active management.
Investment Portfolio Depreciation Debt securities portfolio shows net unrealized depreciation of $384M due to generally increasing interest rates.

Outlook

Optimization Program Continuation Strategic Optimization Program continues through December 2026, expecting future charges for efficiency improvements.
HCSC Remaining Proceeds Expecting remaining $600M cash proceeds from HCSC transaction in fourth quarter of 2025.
Capital Return Intent Company intends regular quarterly dividends; future declarations subject to ongoing Board review and approval.
Debt Management Strategy Actively monitoring debt obligations, engaging in issuance or redemption activities per capital management strategy.

Peer Comparison

Revenue (TTM)

CVS Health CorporationCVS
$394.08B
+6.8%
McKesson CorporationMCK
$387.09B
+17.2%
Cencora, Inc.COR
$321.33B
+9.3%

Gross Margin (Latest Quarter)

GSK plcGSK
73.6%
+3.5pp
Bristol-Myers Squibb CompanyBMY
71.9%
+16.3pp
Zoetis Inc.ZTS
71.5%
+2.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
HCA$117.67B18.4-161.9%77.6%
BMY$106.69B17.734.7%52.7%
MCK$101.72B32.1-124.8%12.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
2.0%
Moderate Growth
4Q Net Income CAGR
9.5%
Profitability Improving
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Jan 29, 2026
|
EPS:$7.90
|
Revenue:$69.30B
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 30, 2025|
    Revenue: $69.75B+9.5%
    |
    EPS: $7.02+164.9%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 31, 2025|
    Revenue: $67.23B+11.1%
    |
    EPS: $5.76+4.5%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 2, 2025|
    Revenue: $65.50B+14.4%
    |
    EPS: $4.72-586.6%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 27, 2025|
    Revenue: $247.12B+26.6%
    |
    EPS: $12.25-30.3%
    Beat
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 31, 2024|
    Revenue: $63.69B+29.9%
    |
    EPS: $2.65-44.7%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 1, 2024|
    Revenue: $60.52B+24.6%
    |
    EPS: $5.51+11.1%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 2, 2024|
    Revenue: $57.26B+23.1%
    |
    EPS: $-0.97-122.7%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 29, 2024|
    Revenue: $195.27B+8.2%
    |
    EPS: $17.39-18.9%
    Miss